Compare PROP & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROP | MCRB |
|---|---|---|
| Founded | 2001 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.9M | 41.2M |
| IPO Year | 2008 | 2015 |
| Metric | PROP | MCRB |
|---|---|---|
| Price | $0.31 | $1.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $1.50 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 1.2M | 88.3K |
| Earning Date | 11-12-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 49.06 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,939,000.00 | $789,000.00 |
| Revenue This Year | $85.81 | $1,648.67 |
| Revenue Next Year | $11.47 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 413.59 | N/A |
| 52 Week Low | $0.30 | $1.30 |
| 52 Week High | $2.55 | $29.98 |
| Indicator | PROP | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 36.77 | 28.78 |
| Support Level | N/A | N/A |
| Resistance Level | $0.44 | $2.26 |
| Average True Range (ATR) | 0.05 | 0.22 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 2.94 | 20.83 |
Prairie Operating Co is an independent oil and natural gas company focused on the acquisition and development of crude oil, natural gas, and natural gas liquids (NGLs). Its assets and operations are located in the oil region of rural Weld County, Colorado, within the Denver-Julesburg Basin in Colorado (the DJ Basin). The company generates maximum revenue from crude oil sales, and the rest from the sale of natural gas and natural gas liquids.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.